Sage Journals: Discover world-class research

Abstract

Social media presents new challenges to the biopharmaceutical industry for conducting pharmacovigilance activities. The authors reviewed worldwide regulatory guidance documents related to monitoring of adverse events posted on social media sites and identified gaps in current regulatory definitions for pharmacovigilance. Points to consider for addressing these gaps are made to offer standards for industry consideration and a potential framework for guidance from global health authorities.

Keywords

pharmacovigilance social media monitoring regulatory harmonization drug safety adverse events on social media

Get full access to this article

View all access options for this article.

References

US Department of Health and Human Services. Guidance for Industry: Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines [draft guidance]. Silver Spring, MD: Center for Biologics Evaluation and Research; 2001.

Aitken

Altmann

Rosen

. Engaging patients through social media. http://www.imshealth.com/portal/site/imshealth/menuitem.762a961826aad98f53c753c71ad8c22a/?vgnextoid=ff71ad0087c73410VgnVCM10000076192ca2RCRD&vgnextchannel=a64de5fda6370410VgnVCM10000076192ca2RCRD. Accessed 2014.

Lamberti

Stergiopoulos

Naik

Getz

. Industry usage of social and digital media communities in clinical research: a Tufts Center for the Study of Drug Development white paper [electronic white paper]. http://csdd.tufts.edu/files/uploads/TCSDD_Social_Media_Final.pdf. Accessed June 2014.

US Department of Health and Human Services. Guidance for Industry Internet/Social Media Platforms With Character Space Limitations: Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices. Silver Spring, MD: Center for Biologics Evaluation and Research; 2014.

US Department of Health and Human Services. Guidance for Industry Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices [draft guidance]. Silver Spring, MD: Center for Biologics Evaluation and Research; 2014.

US Department of Health and Human Services. Guidance for Industry: Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics. Silver Spring, MD: Center for Biologics Evaluation and Research; 2014.

Therapeutic Goods Administration. Australian Requirements and Recommendations for Pharmacovigilance Responsibilities of Sponsors of Medicines. Version 1.3. Canberra, Australia: Department of Health; 2014.

UK Medicines and Healthcare Products Regulatory Agency. Consultative Committee Question and Answer Document. London, England; UK Medicines and Healthcare Products Regulatory Agency; 2012.

European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP) Module VI: Management and Reporting of Adverse Reactions to Medicinal Products—EMA/542040/2014 (superseded version). London, England: European Medicines Agency; 2012.

10.

Pharmaceutical Research and Manufacturers Association. Internet and Social Media Pharmacovigilance Issues: Questions and Answers for Sponsors and Applicants. Washington, DC: Pharmaceutical Research and Manufacturers Association; 2013.

11.

Association of the British Pharmaceutical Industry Pharmacovigilance Expert Network. Guidance Notes on the Management of Adverse Events and Product Complaints From Digital Media. Version 2.0. London, England: Association of the British Pharmaceutical Industry; 2013.

12.

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Post-approval Safety Data Management—Definitions and standards for Expedited Reporting, E2D. Geneva, Switzerland: International Conference on Harmonisation; 2003.

13.

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: E2A. Geneva, Switzerland: International Conference on Harmonisation; 1994.

14.

US Department of Health and Human Services. Guidance for Industry: Postmarketing Adverse Experience Reporting for Human Drug and Licensed Biological Products: Clarification of What to Report. Silver Spring, MD: Center for Biologics Evaluation and Research; 1997.

15.

Health Canada. Guidance document for industry—reporting adverse reactions to marketed health products. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/pubs/medeff/guide/2011-guidance-directrice_reporting-notification-eng.pdf. Published 2011.

16.

Council for International Organizations of Medical Sciences. Current Challenges in Pharmacovigilance: Pragmatic Approaches—Report of CIOMS Working Group 5. Geneva, Switzerland: World Health Organization; 2011.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.42 MB